| O P E N |
ACCR GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| LUNGMAP Screening Protocol Registrations | |||||||||||
| Total | 3577 | 277 | 108 | 43 | 22 | 4 | 02/06/2019 | 424 | 181 | ||
| Screened at PD | 1247 | 55 | 26 | 7 | 3 | 0 | |||||
| Pre-Screened prior to PD | 2330 | 222 | 82 | 36 | 19 | 4 | |||||
| ctDNA Specimen Submission | 315 | 0 | 0 | 0 | 0 | 0 | |||||
| Re-analysis Requests | 498 | 79 | 24 | 3 | 2 | 0 | |||||
| Sub-Study Assignments | |||||||||||
| LUNGMAP Sub-Study Assignments | 1756 | 48 | 25 | 2 | 1 | 0 | |||||
| Screened at PD | 992 | 24 | 11 | 1 | 1 | 0 | |||||
| Pre-Screened prior to PD | 712 | 24 | 14 | 1 | 0 | 0 | |||||
| After PD on a Lung_MAP Sub-Study | 52 | 0 | 0 | 0 | 0 | 0 | |||||
| Sub-Study Assignments (open studies only) | |||||||||||
| S1900G | 27 | 11 | 6 | 0 | 0 | 0 | |||||
| S1900J | 9 | 9 | 9 | 1 | 1 | 0 | |||||
| S1900K | 8 | 7 | 3 | 0 | 0 | 0 | |||||
| Sub-Study Registrations | |||||||||||
| LUNGMAP Sub-Study Registrations | 495 | 21 | 9 | 3 | 0 | 0 | |||||
| Initial sub-study registrations | 483 | 21 | 9 | 3 | 0 | 0 | |||||
| Subsequent sub-study registrations | 12 | 0 | 0 | 0 | 0 | 0 | |||||
| Patients Registered to a Sub-Study (open studies only) | |||||||||||
| S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | 66 | 17 | 8 | 4 | 1 | 0 | 0 | 05/05/2023 | 268 | 101 | |
| Capmatinib + Osimertinib + Ramucirumab | Y | 8 | 4 | 2 | 1 | 0 | 0 | ||||
| Capmatinib + Osimertinib | Y | 9 | 4 | 2 | 0 | 0 | 0 | ||||
| S1900J: MET Amplification: Amivantamab-SC | 88 | 1 | 1 | 1 | 0 | 0 | 0 | 11/19/2024 | 143 | 56 | |
| Amivantamab SC | Y | 1 | 1 | 1 | 0 | 0 | 0 | ||||
| S1900K: MET Exon 14: Tepotinib +/- Ramucirumab | 56 | 3 | 3 | 2 | 1 | 0 | 0 | 08/08/2024 | 245 | 85 | |
| Tepotinib + Ramucirumab | Y | 2 | 2 | 2 | 1 | 0 | 0 | ||||
| Tepotinib | Y | 1 | 1 | 0 | 0 | 0 | 0 | ||||